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Background: Small papillary thyroid carcinomas have contributed to the worldwide increased incidence of
differentiated thyroid cancer observed over the past decades. However, the mortality rate has not changed over
the same period of time, raising questions about the possibility that thyroid cancer patients, especially those
with small tumors, are overdiagnosed and overtreated. Molecular prognostic marker able to discriminate ag-
gressive thyroid cancers from those with an indolent course would be of great relevance to tailor the therapeutic
approach and reduce overtreatment. Mutations in the TERT promoter were recently reported to correlate
strongly with aggressiveness in advanced forms of thyroid cancer, holding promise for a possible clinical
application. The occurrence and potential clinical relevance of TERT mutations in papillary thyroid micro-
carcinomas (mPTCs) is currently unknown. This study aimed to analyze the occurrence of two TERT promoter
mutations (-124C>T and -146C>T) and their potential association with unfavorable clinical features in a large
cohort of mPTCs.
Methods: A total of 431 mPTCs cases were collected from six Italian institutions, and TERT promoter mu-
tational status was assessed by a next-generation sequencing approach.
Results: TERT promoter mutations were found in 4.7% of the analyzed mPTCs, showing that even micro-
carcinomas carry mutations in this gene. Correlation analysis showed that TERT promoter mutations are not
associated with aggressive features or clinical outcome in the cohort analyzed.
Conclusions: TERT mutations are present but uncommon in mPTCs. Apparently, in mPTCs, the occurrence of
TERT mutations is not correlated with unfavorable clinical features.
Introduction
The incidence of thyroid cancer has increased steeplyin the last two decades worldwide. Small papillary thy-
roid carcinomas (mPTCs) account for the major part of this
epidemiological trend (1,2). In this regard, mPTCs, defined as
tumors measuring £ 1 cm, are considered indolent lesions,
with a mortality rate at 10 years of about 0.1% (3). The
relative low aggressiveness of mPTCs has led some authors
to question the necessity of surgical treatment of these tumors
(4). However, mPTCs may correspond to intermediate or
even high-risk neoplasias, given that tumor size is only one
of the components characterizing its behavior (1,5–8). Ac-
cordingly, the presurgical availability of reliable prognostic
molecular markers could allow a more clear-cut risk strati-
fication of mPTCs, thereby leading to amore focused surgical
and therapeutic approach.
Recently, a high frequency of mutations in the promoter of
the Telomerase Reverse Transcriptase (TERT) gene has been
detected in a variety of solid tumors (9–12). In particular, the
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majority of alterations were mapped in two hot spots at
positions -124 bp (chr5:1,295,228 G >A, hereafter termed
-124C >T) and -146 bp (chr5:1,295,250 G >A, hereafter
termed -146C >T) upstream of the transcription starting site
(12). These alterations were found to increase promoter ac-
tivity and TERT expression, most likely introducing new
consensus sites for transcription factors belonging to the ETS
family (9,13,14). In thyroid cancer, mutations in the TERT
promoter have been strongly associated with aggressiveness
and metastatic behavior of the tumors (15–19). In well-
differentiated thyroid cancer, TERT promoter mutations were
reported to occur in < 10% of the lesions, while the incidence
of these mutations increase in thyroid cancers of follicular
origin with distant metastases (>30%) (15,20) and in poorly
differentiated lesions (up to 50%) (17–19). These obser-
vations suggest that TERT promoter mutations could be a
marker to discriminate a subset of aggressive tumors from the
majority of those that are relatively indolent. As of yet, the
occurrence and clinical relevance of TERT promoter muta-
tions in mPTCs is unknown.
The aim of this work, therefore, was to assess the occur-
rence and the frequency of TERT promoter mutations in a
large cohort of mPTCs and to establish whether the presence
of these mutations may hold promise as a useful prognostic
biomarker in this subtype of thyroid cancer.
Material and Methods
Patients
For this study, 431 cases of well-differentiated PTC mea-
suring £ 1 cm (mPTC) were retrieved from the archives of six
different Italian centers (Table 1). Tumor slides were clas-
sified according to the criteria of the World Health Organi-
zation Classification of Tumors (21) and staged according to
AJCC Cancer Staging Manual, 7th edition (22). The histo-
logical variant was evaluated for each mPTC case. Tissues
from 12 lymph node metastases (LNMs) developed from
mPTC were also retrieved and analyzed.
The 431 mPTCs were from 405 patients, since multiple
mPTC lesions were retrieved for 20 patients (2–4 lesions/
patient). Follow-up was available for 306 of the 405 patients,
and ranged from 6 to 170 months (mean 58– 27 months).
Clinical and pathological features of all the cases are sum-
marized in Supplementary Table S1 (Supplementary Data are
available online at www.liebertpub.com/thy). The project
was approved by the local ethics committee.
Sequencing
Next-generation sequencing analysis of the TERT promoter
hot spot harboring the mutations -124C>T and -146C>T was
performed on formalin-fixed and paraffin-embedded (FFPE)-
extracted DNA using the 454 GS-Junior Next Generation se-
quencer (RocheDiagnostics,Mannheim, Germany), according
to established protocols (www.454.com/). Briefly, approxi-
mately 10ngof genomicDNAwere amplified using a FastStart
High Fidelity Taq Polymerase (Roche Diagnostic, Mannheim,
Germany) and the primers Fw 5¢-GGC TCC CAG TGG ATT
CG-3 and Rv 5¢-AAG GAA GGG GAG GGG C-3 ¢, modified
with universal tail sequences and multiple identifiers (MID)
nucleotides (Integrated DNA Technologies, Inc.; www.idtdna
.com).Onlynucleotidevariationsobserved inboth strands, in at
least five reads, and with at least 2% of allele-read frequency at
the position were considered positive. The raw data were an-
alyzed using the Amplicon Variant Analyzer (AVA) Software
(Roche Diagnostics).
BRAFV600E mutation analysis was performed with the
same DNA extracted for the TERT promoter analysis, by
direct sequencing as previously described (23), or by allele-
specific locked nucleic acid polymerase chain reaction, as
previously described (24).
Statistical analysis and bioinformatics analysis
Statistical analyses were performed with R package (R
Foundation for Statistical Computing, Vienna, Austria; www
.R-project.org/). Statistical significance of differences be-
tween groups mean values or frequencies were calculated
by Welsh-corrected Student’s t-test or chi-square test and
Fisher’s exact test, respectively. Association between follow-
up status and TERT mutation status was assessed by logistic
regression analysis. p-Values of < 0.05 were considered as
threshold for significance.
Results
TERT promoter mutations in mPTCs
The mutational status of a hot spot region within the TERT
promoter was successfully analyzed in 404 primary mPTCs.
Table 1. Incidence of TERT Promoter Mutations in mPTC from Different Institutions
Type of TERT mutation
Institution
N of genotyped
mPTC
N of TERT-mutated
mPTC
Frequency of
TERT-mutated mPTC -124C > T -146C > T
RE 201 10 0.049 6 4
BO 79 5 0.06 2 3
SGR 50 0 0 — —
RM 47 3 0.064 2 1
CZ 24 1 0.04 1 —
MT 3 0 0 — —
Overall 404 19 0.047 11 8
RE, Arcispedale S. Maria Nuova, Reggio Emilia, Italy; BO, Bellaria-Maggiore Hospitals, Bologna, Italy; SGR, ‘‘Casa Sollievo della
Sofferenza’’ Hospital—IRCCS in San Giovanni Rotondo, Italy; RM, University Hospital, Universita` ‘‘Sapienza,’’ Rome, Italy; CZ, City
Hospital of Catanzaro, University of Catanzaro, Italy; MT, Tinchi-Pisticci Hospital of Matera, Italy.
mPTC, papillary thyroid microcarcinomas.
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Table 1 summarizes the results of this mutation analysis. The
TERT promoter mutations -124C >T and -146C >T were
found in 19 out of 404 mPTCs, corresponding to 4.7% of
the overall cohort. The -124C >T was the most frequent
mutation, occurring in 11 of the 19 TERT mutated samples,
while the -146C >Twas found in eight mPTCs (Table 1). The
average mutated allele percentage in the 19 TERT mutated
tumors was 7.2 – 5.7% (range 2–17%), suggesting that only a
subgroup of tumor cells harbored the mutations.
Tweleve lymph node metastases (LNMs) were also ana-
lyzed for the presence of the TERT promoter mutations. Two
LNMs derived from patients with TERT mutations in the
primary mPTC, seven derived from six individuals with ab-
sent TERT mutations (two LNMs were from the same wild
type mPTC), and three LNMs originated from subjects whose
primary tumors were not available for molecular analysis.
Overall, 4 of the 12 LNMs (25%) harbored TERT promoter
mutations. Of these, two developed from the same mutated
primary mPTCs, one was acquired de novo in the metastatic
lesion, while in one case the primary mPTCwas not available
for genotyping (Fig. 1). The average percentage of mutated
TERT alleles in the LNMs was 18.8 – 19.1%, (range 4–
46.5%) with an increased percentage of the mutated allele in
the metastatic site compared to the primary lesion (Fig. 1).
Besides the -124C >T and -146C >T mutations, three ad-
ditional mutations were detected in the primary mPTCs and
LNMs, with frequencies comparable to the canonical
-124C >T and -146C >T (Table 2).
TERT promoter mutations and clinical features
of mPTCs
Interestingly, it was found that even mPTCs without ag-
gressive behavior carried mutations in the TERT promoter.
Next, the possible association of the TERT promoter muta-
tions -124C >T and -146C >T with clinicopathological fea-
tures of the included mPTCs (Table 3) was examined. The
presence of a TERT promoter mutation was not associated
with any of the parameters taken into consideration, likely
due to the low frequency of the mutations in the overall co-
hort. It is known that the majority of persistent/recurrent
structural disease (about 77%) in mPTCs occurs within five
years after the initial treatment of the patient (25). The av-
erage follow-up length in our cohort was of 59 months,
without significant differences between the patients with and
without TERT mutations (63.6 – 22.3 vs. 57.5 – 27.3, n.s.).
Within this follow-up period, no significant association be-
tween the presence of these mutations and a negative out-
come was detected (Table 3). However, since mPTCs are
slowly growing tumors, potential effects of TERT promoter
mutations on the progression of these lesions over a longer
period of follow-up cannot be excluded.
Recently, a positive correlation between TERT promoter
mutations and the BRAFV600E mutation was reported in ad-
vanced PTCs, suggesting a functional cooperation (18,20).
The BRAFV600Emutation was successfully analyzed in 428 of
the 431 mPTC samples, and it was detected in 261 mPTCs,
corresponding to 61% of the overall cohort. No statistical
correlation was observed between the presence of TERT
promoter mutations and the occurrence of the BRAFV600E
mutation (Table 3, p = 0.63) in mPTCs. As previously re-
ported (26,27), the BRAFV600E mutation alone was also as-
sociated with tumor size, tall-cell histological variant,
and higher stage in this study. However, the presence of
this mutation did not correlate with the clinical outcomes
(Supplementary Table S2). When considered together, the
FIG. 1. TERT promoter mutation status in matched pri-
mary papillary thyroid microcarcinomas (mPTC; squares)
and lymph node metastases (LNMs; circles). Gray shape are
TERT mutated (type of mutation is indicated, with corre-
sponding mutated allele percentage), white shapes are wild
type.
Table 2. List of Most Frequent Mutations
in TERT Promoter Detected in the Overall
Cohort of Primary mPTC and LNMs
Mutation
N of mutated
lesions
(primary
mPTC
or LNMs)
Frequency
(n of total
lesions = 416)
Average
mutated
allele
percentage
(range), %
-124C >T 14 0.03 9.8 – 11.6 (2–17)
-126C >T 11 0.03 13.9 – 14.0 (5–44)
-161C >T 11 0.03 17.7 – 18.9 (2.5–60)
-138C >T 9 0.02 10.0 – 5.1 (4–19)
-146C >T 9 0.02 8.3 – 6.9 (2–25)
Mutations -126C >T and -138C>T are reported in COSMIC
database with ID: COSM1717363 and COSM1717364, respec-
tively. Their somatic status has not been confirmed. The variation
-161C>T is not reported in the databases.
LNM, lymph node metastasis.
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co-occurrence of a TERT promoter and the BRAFV600E mu-
tation was significantly associated with higher pT and pN,
due to the statistical effect of the BRAFV600E mutation.
Intriguingly, the presence of both mutations was inversely
associated with multifocality (Table 4). Finally, the co-
existence of TERT promoter mutations and BRAFV600E mu-
tation did not affect the clinical outcome in the follow-up
analysis (Table 4).
Discussion
Small thyroid cancers are usually indolent lesions with a
low rate of growth and low metastatic potential. Nonetheless,
a significant percentage of mPTCs (up to 25%) behave ag-
gressively, developing local recurrences, LNMs, and, rarely,
distant metastases (7,28). The identification of prognostic
markers able to discriminate aggressive mPTCs from those
Table 3. Association of TERT Promoter Mutation Status with Clinicopathological Features
of mPTC Lesions and with Patients’ Features and Outcome Status
TERT mut (freq) TERT wt (freq) p-Value
Clinicopathological features of mPTC lesions
Total mPTC (n = 404) 19 (0.047) 385 (0.953) —
Tumor size (mm) 5.9 – 2.9 6.2 – 2.5 0.68
Histological variant 0.59
Classical 8 (0.42) 148 (0.39)
Follicular 9 (0.48) 137 (0.36)
Tall cell 1 (0.05) 66 (0.17)
Solid trabecular 0 (0) 11 (0.03)
Oncocytic 1 (0.05) 17 (0.04)
Multifocality 0.14
Present 4 (0.21) 138 (0.39)
Absent 15 (0.79) 218 (0.61)
pT 0.95
T1 14 (0.74) 273 (0.72)
T3 5 (0.26) 109 (0.28)
pN 0.29
N0 8 (0.42) 201 (0.53)
N1 4 (0.21) 53 (0.14)
Nxa 7 (0.37) 128 (0.33)
Stage 0.62
1 11 (0.73) 271 (0.82)
3 4 (0.27) 58 (0.17)
4a 0 (0) 3 (0.01)
Radioactive iodine therapy 1
No 6 (0.43) 138 (0.45)
Yes 8 (0.57) 171 (0.55)
BRAF mutation status 0.63
Mut 13 (0.68) 236 (0.61)
Wt 6 (0.32) 147 (0.38)
Features and outcome status of mPTC patients
N of patients (n= 381)b 19 (0.05) 362 (0.95) —
Age 50.2 – 11.5 47.8 – 12.8 0.39
Sex 0.77
Female 14 (0.74) 280 (0.78)
Male 5 (0.26) 77 (0.21)
Length of follow-up (months) 63.6 – 22.3 57.5 – 27.3 0.33
Persistent/recurrent disease 0.20
No 11 (0.92) 270 (0.98)
Yes 1 (0.08) 6 (0.02)
Last follow-up status 0.99
No evidence of disease 12 (1) 271 (0.99)
Alive with disease 0 (0) 2 (0.01)
Data are reported as mean– SD or frequencies. In some cases, the clinicopathological features and the outcome status were not available
for every TERT-genotyped mPTC.
aAll the cases were clinically evaluated and the lymph nodes were negative at ultrasound examination.
bFor 20 patients, multiple mPTC lesions were TERT-genotyped (2–4 lesions/patient). For the analysis of association of TERT promoter
status with patient features and outcome status, only one genotype status was utilized for each patient. In 17 patients, the genotype was
concordant (wt) in multiple lesions, in one case the genotype was discordant between three lesions of a single patient (one -124C>T-
mutated, two wt) and the patient was considered as TERT-mutated the analysis.
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with an indolent course would be of great relevance to tailor
the therapeutic approach, avoiding overtreatment, and long-
term surveillance. This study analyzed the occurrence of
TERT promoter mutations in a large cohort of mPTCs. It was
demonstrated that a subset of mPTCs (4.7% of the cohort)
harbored mutations in the TERT promoter. This frequency is
lower than that reported in the literature for PTCs > 1 cm (7–
9%) and significantly lower than that reported for highly
aggressive thyroid carcinomas (up to 51%), suggesting that
the incidence of these mutations increases as the tumor pro-
gresses toward more advanced stages. To the authors’
knowledge, this is one of the first reports in which the pres-
ence of TERT promoter mutations in thyroid cancer has been
assessed using a quantitative approach. While the percentage
of TERT mutated allele was found to be quite low in primary
mPTCs, it increases significantly in the LNMs (up to 46.5%).
This observation suggests a clonal expansion of cells har-
boring TERT promoter mutations during tumor progression.
The overall low prevalence of TERTmutations in small PTCs
comparedwith larger tumors, together with the low percentage
Table 4. Association of TERT Promoter Mutations, BRAF Mutation, and Their Coexistence
with Clinical Features of mPTC and with Patients’ Features and Outcome Status
No mutation
(freq)
Only TERT
mutation (freq) p
Only BRAF
mutation (freq) p
TERT + BRAF
mutations (freq) p
Clinicopathological features of mPTC lesions
Total mPTC (n = 402)a 147 6 236 13
Tumor size (mm) 5.45 – 2.76 4.28 – 2.80 0.35 6.70– 2.19 < 0.001 6.73 – 2.77 0.13
Histological variant 0.58 < 0.001 0.47
Classical 47 (0.32) 1 (0.17) 100 (0.43) 7 (0.54)
Follicular 73 (0.50) 5 (0.83) 64 (0.28) 4 (0.30)
Tall cell 7 (0.05) 0 (0) 58 (0.25) 1 (0.08)
Solid trabecular 8 (0.05) 0 (0) 3 (0.01) 0 (0)
Oncocytic 12 (0.08) 0 (0) 5 (0.02) 1 (0.08)
Multifocality 0.67 0.58 0.03
Present 54 (0.37) 3 (0.50) 84 (0.40) 1 (0.08)
Absent 91 (0.63) 3 (0.50) 125 (0.60) 12 (0.92)
pT 1 < 0.0001 0.03
T1 126 (0.87) 6 (1) 146 (0.62) 8 (0.62)
T3 19 (0.13) 0 (0) 89 (0.38) 5 (0.38)
pN 0.72 0.007 0.03
N0 91 (0.63) 4 (0.66) 109 (0.46) 4 (0.31)
N1 14 (0.10) 0 (0) 38 (0.16) 4 (0.31)
Nxb 40 (0.27) 2 (0.33) 88 (0.38) 5 (0.38)
Stage 0.82 0.05 0.08
1 113 (0.88) 3 (1) 157 (0.78) 8 (0.67)
3 14 (0.11) 0 (0) 43 (0.21) 4 (0.33)
4a 1 (0.01) 0 (0) 2 (0.01) 0 (0)
Radioactive iodine therapy 0.61 0.35 0.54
No 62 (0.48) 2 (0.67) 75 (0.42) 4 (0.36)
Yes 67 (0.52) 1 (0.33) 103 (0.58) 7 (0.64)
Features and outcome status of mPTC patients
N of patients (n = 379) 132 6 228 13
Age 47.2 – 12.3 57.3 – 11.5 0.03 48.3– 13.1 0.67 47 – 10.5 0.77
Sex 1 0.42 0.29
Female 106 (0.81) 5 (0.83) 172 (0.77) 9 (0.69)
Male 25 (0.19) 1 (0.17) 52 (0.23) 4 (0.31)
Length of follow-up (months) 58.1 – 29.9 56.6 – 13.4 0.97 56.8– 26.0 0.94 65.7 – 24.5 0.30
Persistent/recurrent disease 0.99 0.73 0.13
No 108 (0.98) 3 (1) 160 (0.98) 8 (0.89)
Yes 2 (0.02) 0 (0) 4 (0.02) 1 (0.11)
Last follow-up status 0.99 0.77 0.99
No evidence of disease 107 (0.99) 3 (1) 162 (0.99) 9 (1)
Alive with disease 1 (0.01) 0 (0) 1 (0.01) 0 (0)
Comparisons were performed as described in Table 1, between the no mutation group and each of the other three groups (only TERT
mutation; only BRAF mutation; TERT +BRAF mutation).
p-Values refer to the comparison of the no mutation group with the group in the column at the left of the p-value.
Significant values are shown in bold.
aBRAFV600E was not evaluable in two TERT-genotyped mPTC.
bAll the cases were clinically evaluated and the lymph nodes were negative at ultrasound examination.
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of mutated alleles observed in primary mPTCs and its increase
in LNMs, suggest that TERT promoter mutations are late
events in thyroid tumorigenesis and that they confer a func-
tional advance toward aggressiveness and progression.
The present study focused on the two most commonly
analyzed TERT promoter mutations, namely -124C >T and
-146C >T, for which a functional effect on TERT expression
has been experimentally confirmed (9,13,14). However,
within the analyzed hot spot region, three additional muta-
tions were detected with frequencies and allele percentages
comparable with these previously reported mutations. If a
pathogenic role of these mutations is confirmed, the associ-
ation between TERT mutational status and the clinical fea-
tures of mPTCs should be reconsidered by integrating these
new mutations.
In conclusion, this study analyzed for the first time TERT
promoter mutations in a large series of mPTCs. It was ob-
served that TERT promoter mutations do not predict unfa-
vorable features in mPTCs either alone or in combination
with the BRAFV600E mutation, at least within the period of
follow-up considered in this work. This may be partially due
to the low frequency of TERT mutations in this category of
thyroid cancer. It is also needs to be considered that even
though quite a large number of mPTCs were analyzed, none
of them developed distant metastases or an ominous out-
come. The authors have recently shown that TERT pro-
moter mutations are strongly associated with the presence of
distant metastasis but not with the presence of LNMs in well-
differentiated PTCs (15). Thus, the present data seem to
support the concept that TERT promoter mutations are
strongly linked with advanced metastatic spreading, which is
an extremely rare feature in small thyroid carcinomas.
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